A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Adavosertib (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

01 May 2017 Planned initiation date changed from 30 Apr 2017 to 25 May 2017.
20 Apr 2017 Planned initiation date changed from 1 Jan 2017 to 30 Apr 2017.
06 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as Protocol moved to Disapproved .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com